Genmab A/S
NASDAQ:GMAB
Genmab A/S
NASDAQ:GMAB
Price:
29.29
USD
1.35%
Market Closed
Market Cap:
$18.6B
Relative Value
The Relative Value of one
GMAB
stock under the Base Case scenario is
8.7
USD.
Compared to the current market price of 29.29 USD,
Genmab A/S
is
Overvalued by 70%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GMAB
Relative Value
Base Case
8.7
USD
Overvaluation 70%
Multiples Across Competitors
GMAB Competitors Multiples
Genmab A/S Competitors
Genmab A/S Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DK |
|
Genmab A/S
NASDAQ:GMAB
|
113.3B USD | 31.7 | 76.7 | 79.7 | 83.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
399.2B USD | 6.7 | 170 | 16.5 | 23.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD | 5.5 | 26.2 | 15 | 15 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.1B USD | 6.4 | 22.1 | 15 | 15 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121B USD | 10.1 | 30.6 | 23.4 | 24.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD | 5.7 | 18.3 | 13.8 | 15.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.2B AUD | 3.3 | 17.2 | 11.7 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR | 14.2 | 33.5 | 57.5 | 59.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
